Lacerta and Prevail, A Wholly Owned Subsidiary of Lilly, Sign Agreement to Develop Novel AAV Capsids for CNS Disorders

https://www.businesswire.com/news/home/20220823005289/en/Lacerta-and-Prevail-A-Wholly-Owned-Subsidiary-of-Lilly-Sign-Agreement-to-Develop-Novel-AAV-Capsids-for-CNS-Disorders